Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

, NVS

Novartis

$85.65

-0.2 (-0.23%)

05:32
06/03/19
06/03
05:32
06/03/19
05:32

Genentech: POLYP 1, POLYP 2 Phase III trials met co-primary, secondary endpoints

Genentech, a member of the Roche Group (RHHBY), announced positive topline data from two Phase III multicenter studies evaluating Xolair for the treatment of adults with chronic rhinosinusitis with nasal polyps, or CRSwNP, who have not adequately responded to intranasal corticosteroids. The POLYP 1 and POLYP 2 Phase III trials met both co-primary endpoints and key secondary endpoints. Xolair, an injectable biologic medicine designed to target and block immunoglobulin E, or IgE, was shown to be well tolerated and the safety profile was consistent with that observed in previous studies in people with moderate to severe allergic asthma and chronic idiopathic urticaria. The co-primary endpoints of POLYP 1 and POLYP 2 were change from baseline in Nasal Polyp Score and change from baseline in average daily Nasal Congestion Score over 24 weeks. Xolair demonstrated statistically significant and clinically relevant improvements in both of these co-primary outcomes. Patients enrolled in the study included those with and without a history of surgery. Key secondary endpoints were met, including improvement in smell, post-nasal drip, runny nose and the Sino-Nasal Outcome Test-22, or SNOT-22, health-related quality of life assessment. In the U.S., Genentech and Novartis Pharmaceuticals (NVS) work together to develop and co-promote Xolair.

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$85.65

-0.2 (-0.23%)

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 20

    Jun

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

RHHBY Roche
$0.00

(0.00%)

04/22/19
BMOC
04/22/19
NO CHANGE
Target $96
BMOC
Outperform
Ionis Pharmaceuticals price target raised to $96 from $82 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Ionis Pharmaceuticals (IONS) to $96 and kept his outperform rating after including the risk-adjusted royalties for HTT-Rx in his model as part of the update on its partnership with Roche (RHHBY) disclosed last month. The analyst notes that the stock price has started to reflect the company's Huntington's disease opportunity based on the "potential for an accelerated path with Phase 2 data" and believes that his HTT-Rx projections could prove to be "conservative".
05/09/19
LEHM
05/09/19
NO CHANGE
Target $245
LEHM
Equal Weight
Barclays cuts Biogen target to $245 on reduced Spinraza estimates
Barclays analyst Geoff Meacham lowered his price target for Biogen (BIIB) to $245 from $250 citing growing uncertainty in spinal muscular atrophy. Concerns over Spinraza in spinal muscular atrophy have intensified with the impending launch of Novartis' (NVS) gene therapy Zolgensma and Roche (RHHBY)/PTC's (PTCT) oral risdiplam, Meacham tells investors in a research note. The analyst says his feedback from key opinion leaders was "direct and unequivocal," with the leaders predicting "robust uptake" of both Zolgensma and risdiplam given signs of improved efficacy. This was at the expense of Spinraza driven by the clinical burden of intrathecal injections, says Meacham. On the basis of this feedback, he lowered his longer-term Spinraza outlook by ~$150M per year. The analyst now forecasts sales of $2.0B in 2019, declining to $1.7B in 2023. He keeps an Equal Weight rating on Biogen.
05/23/19
RBCM
05/23/19
NO CHANGE
Target $143
RBCM
Outperform
RBC sees 'interesting parallels' between Intercept and Roche-acquired InterMune
RBC Capital analyst Brian Abrahams said in a new note to investors that he sees "a number of interesting parallels" between Intercept (ICPT) and InterMune, which he notes was acquired by Roche (RHHBY) for $8.3B in 2014. While he admits that "it is not a perfect apples-to-apples comparison," he highlights that both companies' lead drugs had tolerability questions and finite exclusivity periods and that competitive risks have been "overly hyped" for Intercept's obeticholic acid and InterMune's Esbriet. The analyst, who contends that the similarities "further highlight the significant valuation disconnect" for Intercept, keeps an Outperform rating and $143 price target on the shares.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
NVS Novartis
$85.65

-0.2 (-0.23%)

05/17/19
FBCO
05/17/19
NO CHANGE
Target $68
FBCO
Outperform
Alcon off to 'solid start' post-Novartis spin, says Credit Suisse
Credit Suisse analyst Matt Miksic reiterated an Outperform rating on Alcon (ALC) and raised his price target to $68 from $66 following the company's quarterly results, saying Alcon is off to a "solid start" following the spinoff from Novartis (NVS), and says he is incrementally more bullish on the company's revenue and growth drivers.
05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.
05/24/19
FBCO
05/24/19
NO CHANGE
FBCO
Underperform
Zolgensma label breadth on higher end of expectations, says Credit Suisse
Credit Suisse analyst Evan Seigerman noted that the FDA announced approval for Novartis' (NVS) Zolgensma for the treatment of Spinal Muscular Atrophy, or SMA, in patients with bi-allelic mutations in the SMN1 gene under 2 years of age. The current wholesale acquisition cost for Biogen's (BIIB) Spinraza equates to a per-year treatment cost of $500,000 for the first year loading phase and $250,000-$375,000 per year for maintenance thereafter, which compares to a WAC of $2.125M for Zolgensma, which is administered just once, noted Seigerman. While investors generally expected Zolgensma would be approved, the breadth of the label was on the higher end of expectations, Seigerman tells investors. The pricing and label support his below consensus view of Spinraza, as he continues to expect that Zolgensma will become the preferred first option for infant-onset type 1 SMA, said the analyst, who reiterates his $198 price target and Underperform rating on Biogen shares.

TODAY'S FREE FLY STORIES

CTST

CannTrust

$0.83

-0.085 (-9.29%)

12:30
10/14/19
10/14
12:30
10/14/19
12:30
Hot Stocks
Breaking Hot Stocks news story on CannTrust »

CannTrust Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USAT

USA Technologies

$0.00

(0.00%)

12:25
10/14/19
10/14
12:25
10/14/19
12:25
Hot Stocks
USA Technologies says proposal to work with Hudson rejected by Braunstein »

USA Technologies issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AYX

Alteryx

$113.99

2.33 (2.09%)

12:25
10/14/19
10/14
12:25
10/14/19
12:25
Options
Alteryx call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
10/14/19
10/14
12:17
10/14/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
10/14/19
10/14
12:16
10/14/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HGV

Hilton Grand Vacations

$32.59

-0.09 (-0.28%)

12:12
10/14/19
10/14
12:12
10/14/19
12:12
Hot Stocks
Breaking Hot Stocks news story on Hilton Grand Vacations »

Hilton Grand Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HGV

Hilton Grand Vacations

$32.59

-0.09 (-0.28%)

, APO

Apollo Global

$38.61

-0.11 (-0.28%)

12:11
10/14/19
10/14
12:11
10/14/19
12:11
Hot Stocks
Hilton Grand Vacations jumps after Apollo Global said to bid $40 per share »

Shares of Hilton Grand…

HGV

Hilton Grand Vacations

$32.59

-0.09 (-0.28%)

APO

Apollo Global

$38.61

-0.11 (-0.28%)

BX

Blackstone

$46.23

-0.87 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

  • 07

    Nov

DB

Deutsche Bank

$7.57

0.1 (1.34%)

12:10
10/14/19
10/14
12:10
10/14/19
12:10
Periodicals
Deutsche Bank lavished gifts in China to win business, NY Times reports »

In a campaign to win…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

HGV

Hilton Grand Vacations

$32.60

-0.08 (-0.24%)

, APO

Apollo Global

$38.60

-0.12 (-0.31%)

12:08
10/14/19
10/14
12:08
10/14/19
12:08
Periodicals
Breaking Periodicals news story on Hilton Grand Vacations, Apollo Global »

Apollo said to bid near…

HGV

Hilton Grand Vacations

$32.60

-0.08 (-0.24%)

APO

Apollo Global

$38.60

-0.12 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 07

    Nov

HGV

Hilton Grand Vacations

$32.60

-0.08 (-0.24%)

12:06
10/14/19
10/14
12:06
10/14/19
12:06
Hot Stocks
Breaking Hot Stocks news story on Hilton Grand Vacations »

Hilton Grand Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARE

Ultragenyx

$42.08

-0.69 (-1.61%)

12:05
10/14/19
10/14
12:05
10/14/19
12:05
Conference/Events
Ultragenyx participates in a conference call with JPMorgan »

Large Cap Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

GGAL

Grupo Financiero

$12.99

-0.06 (-0.46%)

12:05
10/14/19
10/14
12:05
10/14/19
12:05
Options
Grupo Financiero call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
10/14/19
10/14
11:55
10/14/19
11:55
Conference/Events
JPMorgan telecom/networking equip analyst holds analyst/industry conference call »

Telecom & Networking…

VST

Vistra Energy

$27.00

-0.08 (-0.30%)

11:55
10/14/19
10/14
11:55
10/14/19
11:55
Options
Vistra Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDC

SmileDirectClub

$10.11

-0.99 (-8.92%)

11:50
10/14/19
10/14
11:50
10/14/19
11:50
On The Fly
SmileDirectClub drops after Dental Board of California sunset bill signed »

Shares of SmileDirectClub…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

RVNC

Revance

$13.01

0.84 (6.90%)

11:47
10/14/19
10/14
11:47
10/14/19
11:47
Recommendations
Revance analyst commentary  »

Stifel surprised by CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

HAL

Halliburton

$18.43

-0.515 (-2.72%)

11:45
10/14/19
10/14
11:45
10/14/19
11:45
Options
Halliburton call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 13

    Nov

NKE

Nike

$94.87

0.97 (1.03%)

, WDC

Western Digital

$59.11

0.75 (1.29%)

11:41
10/14/19
10/14
11:41
10/14/19
11:41
On The Fly
Nike, Western Digital upgrades among today's top analyst calls »

Check out today's top…

NKE

Nike

$94.87

0.97 (1.03%)

WDC

Western Digital

$59.11

0.75 (1.29%)

TPR

Tapestry

$24.94

-1.03 (-3.97%)

HPE

HP Enterprise

$14.77

0.42 (2.93%)

XLNX

Xilinx

$96.33

0.15 (0.16%)

DAL

Delta Air Lines

$52.71

-0.23 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 07

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

SDC

SmileDirectClub

$10.33

-0.77 (-6.94%)

11:32
10/14/19
10/14
11:32
10/14/19
11:32
Recommendations
SmileDirectClub analyst commentary  »

SmileDirectClub may have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

INTC

Intel

$51.65

-0.41 (-0.79%)

11:28
10/14/19
10/14
11:28
10/14/19
11:28
Periodicals
Intel may skip 10nm for desktop CPUs, Wccftech reports »

Intel is planning to skip…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 20

    Nov

BKNG

Booking Holdings

$1,985.99

11.08 (0.56%)

, FB

Facebook

$183.97

-0.23 (-0.12%)

11:25
10/14/19
10/14
11:25
10/14/19
11:25
Periodicals
Booking Holdings no longer supporting Facebook's Libra cryptocurrency, CNBC says »

CNBC Now tweeted…

BKNG

Booking Holdings

$1,985.99

11.08 (0.56%)

FB

Facebook

$183.97

-0.23 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

M

Macy's

$15.17

-0.56 (-3.56%)

11:25
10/14/19
10/14
11:25
10/14/19
11:25
Options
Macy's call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CARA

Cara Therapeutics

$19.13

0.29 (1.54%)

11:22
10/14/19
10/14
11:22
10/14/19
11:22
Recommendations
Cara Therapeutics analyst commentary  »

Stifel still optimistic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZUL

Azul

$37.10

0.25 (0.68%)

, UAL

United Airlines

$86.50

-0.68 (-0.78%)

11:20
10/14/19
10/14
11:20
10/14/19
11:20
Periodicals
Azul in talks to join United, Copa, Avianca partnership, Reuters reports »

Brazilian airline Azul…

AZUL

Azul

$37.10

0.25 (0.68%)

UAL

United Airlines

$86.50

-0.68 (-0.78%)

CPA

Copa Holdings

$98.68

-0.67 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 12

    Nov

  • 14

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
10/14/19
10/14
11:17
10/14/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.